Madrigal Pharmaceuticals, Inc.
Simbolis: MDGL
NASDAQ
229.84
USDRinkos kaina šiandien
-12.1269
P/E santykis
-0.3892
PEG koeficientas
4.83B
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Madrigal Pharmaceuticals, Inc. (MDGL) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1494.38 | 634.1 | 358.8 | 270.3 | ||||||||||||||||||||||
balance-sheet.row.short-term-investments | 1141.9 | 534.2 | 27.2 | 234.1 | ||||||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.other-current-assets | 11.25 | 3.1 | 2.6 | 1.3 | ||||||||||||||||||||||
balance-sheet.row.total-current-assets | 1505.63 | 637.3 | 361.4 | 271.7 | ||||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 7.79 | 3.3 | 1.2 | 1.6 | ||||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 7.79 | 3.3 | 1.2 | 1.6 | ||||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.total-assets | 1513.42 | 640.5 | 362.6 | 273.3 | ||||||||||||||||||||||
balance-sheet.row.account-payables | 74.25 | 28 | 23.8 | 21.4 | ||||||||||||||||||||||
balance-sheet.row.short-term-debt | 2.1 | 0.5 | 0.6 | 0.4 | ||||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 414.74 | 115.5 | 49.3 | 0.4 | ||||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||||||
balance-sheet.row.other-current-liab | 339.92 | 90 | 91.5 | 55 | ||||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 415.93 | 116.7 | 49.3 | 0.4 | ||||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 4.09 | 1.2 | 0.6 | 0.8 | ||||||||||||||||||||||
balance-sheet.row.total-liab | 832.2 | 235.2 | 165.2 | 77.2 | ||||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.common-stock | 0.01 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.retained-earnings | -4725.3 | -1336.3 | -962.7 | -667.3 | ||||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0.25 | 0.5 | 0 | -0.1 | ||||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 5406.26 | 1741.2 | 1160.1 | 863.5 | ||||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 681.22 | 405.3 | 197.4 | 196.1 | ||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1513.42 | 640.5 | 362.6 | 273.3 | ||||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.total-equity | 681.22 | 405.3 | 197.4 | 196.1 | ||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1513.42 | - | - | - | ||||||||||||||||||||||
Total Investments | 1141.9 | 534.2 | 27.2 | 234.1 | ||||||||||||||||||||||
balance-sheet.row.total-debt | 418.03 | 117.2 | 49.9 | 0.8 | ||||||||||||||||||||||
balance-sheet.row.net-debt | 65.56 | 17.3 | -281.7 | -35.5 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -373.63 | -373.6 | -295.4 | -241.8 | |||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.53 | 0.5 | 0.5 | 0.4 | |||||||||||||||||||||
cash-flows.row.deferred-income-tax | -3.64 | -4.2 | 0 | -7.3 | |||||||||||||||||||||
cash-flows.row.stock-based-compensation | 49.73 | 49.7 | 31.6 | 26.9 | |||||||||||||||||||||
cash-flows.row.change-in-working-capital | -3.28 | -3.3 | 37.6 | 30.7 | |||||||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.account-payables | 4.21 | 4.2 | 2.5 | 20.4 | |||||||||||||||||||||
cash-flows.row.other-working-capital | 11.49 | -7.5 | 35.2 | 10.3 | |||||||||||||||||||||
cash-flows.row.other-non-cash-items | 6.05 | 6.6 | 0.8 | 7.3 | |||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -324.23 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -1.48 | -1.5 | -0.2 | -0.2 | |||||||||||||||||||||
cash-flows.row.acquisitions-net | -1.85 | -5.5 | 0 | 0.8 | |||||||||||||||||||||
cash-flows.row.purchases-of-investments | -834.44 | -834.4 | -143.5 | -394.1 | |||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 333.4 | 333.4 | 350.4 | 389.3 | |||||||||||||||||||||
cash-flows.row.other-investing-activites | 1.85 | 5.5 | 0 | -0.8 | |||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -502.52 | -502.5 | 206.7 | -5.1 | |||||||||||||||||||||
cash-flows.row.debt-repayment | -64.64 | -64.6 | -49.1 | 0 | |||||||||||||||||||||
cash-flows.row.common-stock-issued | 504.4 | 530.5 | 255.4 | 170.2 | |||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.other-financing-activites | 155.83 | 129.3 | 107.2 | 1 | |||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 595.12 | 595.1 | 313.5 | 171.2 | |||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 58.06 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.net-change-in-cash | -231.63 | -231.6 | 295.3 | -17.7 | |||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 352.47 | 99.9 | 331.5 | 36.3 | |||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 584.11 | 331.5 | 36.3 | 54 | |||||||||||||||||||||
cash-flows.row.operating-cash-flow | -324.23 | -324.2 | -224.9 | -183.9 | |||||||||||||||||||||
cash-flows.row.capital-expenditure | -1.48 | -1.5 | -0.2 | -0.2 | |||||||||||||||||||||
cash-flows.row.free-cash-flow | -325.71 | -325.7 | -225.1 | -184.1 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0.53 | 0.5 | 0.5 | 0.4 | |||||||||||||||||||||||
income-statement-row.row.gross-profit | -0.53 | -0.5 | -0.5 | -0.4 | |||||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
income-statement-row.row.research-development | 272.21 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 108.15 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0.3 | |||||||||||||||||||||||
income-statement-row.row.operating-expenses | 380.35 | 380 | 293.6 | 242.5 | |||||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 380.5 | 380.5 | 293.6 | 242.5 | |||||||||||||||||||||||
income-statement-row.row.interest-income | 19.58 | 19.6 | 2.2 | 0.4 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 5.7 | 12.7 | 4 | 0 | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 6.87 | 6.9 | -1.8 | 0.6 | |||||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0.3 | |||||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 6.87 | 6.9 | -1.8 | 0.6 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 5.7 | 12.7 | 4 | 0 | |||||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 4.3 | 0.5 | 2.2 | 0.4 | |||||||||||||||||||||||
income-statement-row.row.ebitda-caps | -372.9 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.operating-income | -380.5 | -380.5 | -293.6 | -242.5 | |||||||||||||||||||||||
income-statement-row.row.income-before-tax | -373.63 | -373.6 | -295.4 | -241.8 | |||||||||||||||||||||||
income-statement-row.row.income-tax-expense | 4.19 | 0 | 4 | -0.8 | |||||||||||||||||||||||
income-statement-row.row.net-income | -374.53 | -373.6 | -299.3 | -241.1 |
Dažnai užduodami klausimai
Kas yra Madrigal Pharmaceuticals, Inc. (MDGL) bendras turtas?
Madrigal Pharmaceuticals, Inc. (MDGL) bendras turtas yra 640547000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.000.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -16.483.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.000.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.000.
Kas yra Madrigal Pharmaceuticals, Inc. (MDGL) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -373630000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 117193000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 379969000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 99915000.000.